In this review:
- LAURA: CNS and distant progression results
- ALINA: exploratory biomarker analyses
- Adjuvant durvalumab in early stage, completely resected NSCLC
- RELATIVITY-104: first-line nivolumab + relatlimab + platinum-doublet chemotherapy for NSCLC
- PIONeeR: overcoming resistance to anti-PD(L)-1 in advanced NSCLC
- ALKOVE-1: a fourth-generation ALK inhibitor for ALK+ solid tumours
- REZILIENT1: zipalertinib in NSCLC with EGFR exon 20 insertion mutations after progression with amivantamab
- PRT3789: A novel SMARCA2 degrader in advanced solid tumours with SMARCA4 mutations
- ARROS-1: zidesamtinib in ROS1 fusion-positive solid tumours
- PECATI: lenvatinib + pembrolizumab in pretreated advanced B3-thymoma & thymic carcinoma
Please login below to download this issue (PDF)